Insulet Newswire

Insulet Newswire

Comprehensive Real-Time News Feed for Insulet.

Results 1 - 20 of 416 in Insulet

  1. JPMorgan Chase & Co. Has $34.04 Million Holdings in Insulet Co.Read the original story w/Photo

    Tuesday | The Breeze

    JPMorgan Chase & Co. raised its stake in Insulet Co. by 104.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.

    Comment?

  2. American International Group Inc. Has $2.15 Million Stake in Insulet Co.Read the original story w/Photo

    Monday Dec 11 | Daily Political

    American International Group Inc. grew its position in shares of Insulet Co. by 8.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission.

    Comment?

  3. Insulet (PODD) vs. Delcath Systems (DCTHD) Head to Head SurveyRead the original story w/Photo

    Sunday Dec 10 | AmericanBankingNews.com

    Insulet and Delcath Systems are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends. Delcath Systems has lower revenue, but higher earnings than Insulet.

    Comment?

  4. Delcath Systems (DCTHD) versus Insulet (PODD) Financial ComparisonRead the original story w/Photo

    Sunday Dec 10 | IntersportsWire

    Delcath Systems and Insulet are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation. Delcath Systems has a beta of -0.59, suggesting that its share price is 159% less volatile than the S&P 500.

    Comment?

  5. Insulet (PODD) & Delcath Systems (DCTHD) Critical ReviewRead the original story w/Photo

    Sunday Dec 10 | AmericanBankingNews.com

    Insulet and Delcath Systems are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk. Insulet currently has a consensus target price of $60.54, suggesting a potential downside of 13.22%.

    Comment?

  6. Insulet Co. (PODD) is Think Investments LP's 4th Largest PositionRead the original story w/Photo

    Sunday Dec 10 | IntersportsWire

    Think Investments LP trimmed its position in Insulet Co. by 11.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission .

    Comment?

  7. Critical Review: Delcath SystemsRead the original story w/Photo

    Friday Dec 8 | AmericanBankingNews.com

    Delcath Systems and Insulet are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership. Insulet has a consensus price target of $60.54, indicating a potential downside of 13.22%.

    Comment?

  8. Insulet (PODD) Receiving Somewhat Positive Media Coverage, Accern ReportsRead the original story w/Photo

    Thursday Dec 7 | IntersportsWire

    News articles about Insulet have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time.

    Comment?

  9. -$0.07 EPS Expected for Insulet Co. (PODD) This QuarterRead the original story w/Photo

    Wednesday Dec 6 | AmericanBankingNews.com

    Equities analysts predict that Insulet Co. will announce earnings of per share for the current quarter, according to Zacks Investment Research .

    Comment?

  10. Comparing InsuletRead the original story w/Photo

    Tuesday Dec 5 | Daily Political

    Insulet and Delcath Systems are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership. Insulet presently has a consensus target price of $60.54, suggesting a potential downside of 13.08%.

    Comment?

  11. Insulet (PODD) Downgraded by BidaskClub to a oeHoldaRead the original story w/Photo

    Sunday Dec 3 | The Breeze

    Complete the form below to receive the latest headlines and analysts' recommendationsfor Insulet Corporation with our free daily email newsletter: Other research analysts also recently issued research reports about the stock. Oppenheimer set a $55.00 price objective on shares of Insulet and gave the stock a hold rating in a report on Friday, August 4th.

    Comment?

  12. Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Insulet (PODD) Stock PriceRead the original story w/Photo

    Sunday Dec 3 | The Breeze

    News headlines about Insulet have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time.

    Comment?

  13. Insulet (PODD) Downgraded to "Hold" at BidaskClubRead the original story w/Photo

    Saturday Dec 2 | Daily Political

    PODD has been the subject of a number of other research reports. Jefferies Group restated a "buy" rating and set a $58.00 price objective on shares of Insulet in a research report on Wednesday, August 9th.

    Comment?

  14. Insulet (PODD) Downgraded to Hold at BidaskClubRead the original story w/Photo

    Saturday Dec 2 | AmericanBankingNews.com

    PODD has been the topic of several other research reports. Barclays assumed coverage on Insulet in a research note on Friday, September 15th.

    Comment?

  15. Insulet Corporation (PODD) Given Average Rating of "Buy" by BrokeragesRead the original story w/Photo

    Thursday Nov 30 | AmericanBankingNews.com

    Insulet Corporation has earned an average recommendation of "Buy" from the nineteen analysts that are presently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company.

    Comment?

  16. Efficacy of the Omnipod Insulin Management System on Glycemic Control ...Read the original story

    Thursday Nov 30 | CiteULike

    ... in patients with type 1 diabetes (n = 873) after 3 months treatment the Omnipod(A ) insulin management system (Insulet Corporation, Billerica, MA) compared to prior treatment with multiple daily injections (MDI) (78.1%) or CSII (21.9%). The primary ...

    Comment?

  17. Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Insulet (PODD) Stock PriceRead the original story w/Photo

    Tuesday Nov 28 | IntersportsWire

    News stories about Insulet have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time.

    Comment?

  18. Insulet (PODD) versus Delcath Systems (DCTHD) Head-To-Head ReviewRead the original story w/Photo

    Tuesday Nov 28 | AmericanBankingNews.com

    Insulet and Delcath Systems are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings. Insulet has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.

    Comment?

  19. Insulet (PODD) vs. Delcath Systems (DCTHD) Head-To-Head ReviewRead the original story w/Photo

    Monday Nov 27 | IntersportsWire

    Insulet and Delcath Systems are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations. This is a breakdown of recent ratings and target prices for Insulet and Delcath Systems, as provided by MarketBeat.com.

    Comment?

  20. Critical Contrast: Delcath SystemsRead the original story w/Photo

    Monday Nov 27 | The Breeze

    Delcath Systems and Insulet are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership. Delcath Systems has higher revenue, but lower earnings than Insulet.

    Comment?